-
- Rino Rappuoli
- Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy;
-
- Ennio De Gregorio
- Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy;
-
- Giuseppe Del Giudice
- Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy;
-
- Sanjay Phogat
- Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy;
-
- Simone Pecetta
- Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy;
-
- Mariagrazia Pizza
- Research and Development Centre, GlaxoSmithKline (GSK), 53100 Siena, Italy;
-
- Emmanuel Hanon
- Research and Development Centre, GlaxoSmithKline (GSK), 1330 Rixensart, Belgium
説明
<jats:p>The COVID-19 pandemic is a shocking reminder of how our world would look in the absence of vaccination. Fortunately, new technologies, the pace of understanding new and existing pathogens, and the increased knowledge of the immune system allow us today to develop vaccines at an unprecedented speed. Some of the vaccine technologies that are fast-tracked by the urgency of COVID-19 may also be the answer for other health priorities, such as antimicrobial resistance, chronic infections, and cancer, that the post-COVID-19 world will urgently need to face. This perspective analyzes the way COVID-19 is transforming vaccinology and the opportunities for vaccines to have an increasingly important role in health and well-being.</jats:p>
収録刊行物
-
- Proceedings of the National Academy of Sciences
-
Proceedings of the National Academy of Sciences 118 (3), 2021-01-11
Proceedings of the National Academy of Sciences